Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Jun. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Eric Venker [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On June 30, 2026, Eric Venker, President and Immunovant CEO of our subsidiary Roivant Sciences, Inc., entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 1,787,943 common shares held by Dr. Venker between October 20, 2026 and October 20, 2027.
|
| Name | Eric Venker |
| Title | President and Immunovant CEO |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | June 30, 2026 |
| Expiration Date | October 20, 2027 |
| Arrangement Duration | 365 days |
| Aggregate Available | 1,787,943 |